

#### 4.0.03 DOC Cmte minutes

### Urinary Tract Infection (recurrent): antimicrobial prescribing Committee meeting

**Date:** 17/07/2024

**Location:** Via Zoom

**Minutes:** Final

**NICE** National Institute for  
Health and Care Excellence

<b>Committee members present:</b>	
Phil Taverner (Chair)	Present for notes 1 - 5
Markus Drake	Present for notes 1 - 5
Catriona Anderson	Present for notes 1 - 5
Hayley Berry	Present for notes 1 - 5
Ian Hill-Smith	Present for notes 1 - 5
Claire Jowett	Present for notes 1 - 5
Sarah Logan	Present for notes 1 - 5
Rajvinder Kaur Khasriya	Present for notes 1 - 5
Hazel Frost	Present for notes 1 - 5

<b>In attendance:</b>		
Lisa Boardman	NICE Topic Lead	(Present for items 1 – 5)
Daniel Davies	NICE Project Manager	(Present for items 1 – 5)
Laura Elliff-O'Shea	NICE Senior Technical Analyst	(Present for items 1 – 5)
Anja Fricke	NICE Technical Analyst	(Present for items 1 – 5)
Syed Mohiuddin	Senior Health Economist	(Present for items 1 – 5)
Kusal Lokuge	Health Economist	(Present for items 1 – 5)
Emma Clegg	NICE Senior Information Specialist	(Present for items 1 – 5)
Bethan Dorsett	Senior Medical Editor	(Present for items 1 – 5)

#### 4.0.03 DOC Cmte minutes

Edgar Masanga	Business Analyst, Resource Impact Assessment	(Present for items 1 – 5)
---------------	----------------------------------------------	---------------------------

#### Apologies:

None

#### 1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the third meeting on Urinary Tract Infection (recurrent): antimicrobial prescribing. The Committee members and attendees introduced themselves.

The Chair informed the Committee that apologies had been received. These are noted above.

No new declarations were declared.

#### 2. Next steps after today – consultation process

The Chair introduced Lisa Boardman, Topic Lead who advised of the next steps in the process and what the committee could expect.

#### 3. Recap of draft recommendations for methenamine hippurate

The Chair introduced Lisa Boardman, Topic Lead, Laura Eiliff-O'Shea, Senior Technical Analyst, Anja Fricke, Technical Analyst who presented the recommendations made for methenamine hippurate.

The committee considered the proposed editorial changes and discussed any potential equality impact assessment issues.

#### 4. Review of committee discussion sections of the evidence report re draft recommendations for methenamine hippurate

The Chair introduced Lisa Boardman, Topic Lead, Laura Eiliff-O'Shea, Senior Technical Analyst and Anja Fricke, Technical Analyst and Kusal Lokuge, Health Economist who presented the committee discussion sections of the evidence report for committee review

The committee discussed any changes required and the NICE team made amendments where needed.

#### 4.0.03 DOC Cmte minutes

<b>5. Consideration of resource implications when implementing new recommendations</b>
<p>The chair introduced Edgar Masanga, Business Analyst in the Resource Impact Team, who presented an update on any resource impacts that would come about following recommendations.</p> <p>The committee reviewed and discussed these.</p>
<b>6. Discuss and agree further minor edits to the guideline in consideration of Gender and trans people, and Vaginal Oestrogen.</b>
<p>The Chair introduced Lisa Boardman, Topic Lead and Bethan Dorsett, Senior guideline content designer, who presented the committee with proposed changes to the wording in some areas of the guideline.</p> <p>The committee discussed these and agreed amendments.</p>
<b>7. Any final thoughts from the committee to feed back to the NICE surveillance team and prioritisation board regarding future updates of UTI NICE guidelines</b>
<p>The committee discussed anything they would like to be taken forward for consideration for any future updates of the guideline by NICE.</p>
<b>8. Next Steps and any other business</b>
<p>The chair updated the committee on the next steps and key dates that the guideline would follow.</p>
<b>5. Any other business</b>
<p>There was no other business for discussion. The chair thanked the committee for their time and advised that the next meeting would be on 20 September 2024.</p>
<b>Meeting Close</b>

**Date of next meeting:** 20/09/2024

**Location of next meeting:** Via Zoom